Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 44 of 6351
-
New drug cocktail aims to stop leukemia return after transplant
Disease control Not yet recruitingThis study evaluates the efficacy and safety of maintenance therapy with lisaftoclax plus azacitidine after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adults with acute myeloid leukemia (AML) at high risk of relapse. The main questions this study aims to a…
Phase 3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
A blood and stool test could spot digestive cancers before they spread
Diagnosis Recruiting nowThis project aims to evaluate the sensitivity and specificity of combined blood multi-gene methylation and fecal biomarkers for pan-digestive tract cancer screening, so as to establish a novel technical system for the early diagnosis of pan-digestive tract cancers.Individuals sch…
Sponsor: Xijing Hospital • Aim: Diagnosis
Last updated Aug 20, 2026 00:00 UTC
-
Can a cheaper copy of a leukemia drug work just as well?
Disease control Not yet recruitingA Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Study to Compare the Similarities in Pharmacokinetics, Efficacy, Safety and Immunogenicity Between Injectable BLB101 and Blincyto® in Adult Participants with R/R CD19+ B-ALL. Provide evidence for the approval a…
Phase 3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Could an arthritis drug stop type 1 diabetes before it starts?
Prevention Not yet recruitingThe goal of this clinical trial is to learn if golimumab is effective at preventing progression to Stage 2 diabetes in participants with presymptomatic Type 1 Diabetes. The expected duration of this study is approximately 6 years. Participants will: * Take golimumab or placebo …
Phase 2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Prevention
Last updated Jul 08, 2026 00:00 UTC
-
New shot could tame tough eczema by calming overactive immune cells
Disease control Recruiting nowThis is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall d…
Phase 3 • Sponsor: Nektar Therapeutics • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a Two-Drug combo stop colorectal cancer from coming back?
Disease control Not yet recruitingThe primary objective of this study is to evaluate the effectiveness of zanzalintinib + Pembrolizumab (+) berahyaluronidase alfa and zanzalintinib alone compared with placebo.
Phase 3 • Sponsor: Exelixis • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a short Pre-Surgery immunotherapy course replace Long-Term adjuvant treatment for melanoma?
Disease control Not yet recruitingThis study evaluates the impact of neoadjuvant Programmed cell death Protein 1 (PD-1)-based treatment regimens in patients with resectable stage IIIB-M1a cutaneous or unknown primary melanoma at high risk of relapse without adjuvant therapy after definitive lymphadenectomy and ir…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can tailored radiation outsmart Drug-Resistant lung cancer in the brain?
Disease control Recruiting now\*\*Brief Summary (English)\*\* The goal of this clinical trial is to learn if a risk-adaptive consolidation therapy, guided by cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) clearance kinetics after induction intrathecal pemetrexed, can improve intracranial progression…
Sponsor: Shuanghu Yuan • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a missing protein be replaced to slow Friedreich's ataxia?
Disease control Recruiting nowTo evaluate the efficacy and safety of subcutaneous nomlabofusp in adult and pediatric subjects with Friedreich's ataxia
Phase 3 • Sponsor: Larimar Therapeutics, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Hope for rare disease: new drug trial for VEXAS syndrome begins
Disease control Not yet recruitingThis study will assess the efficacy and safety of momelotinib in participants with a diagnosis of VEXAS.
Phase 2/3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Can a new pill shorten COVID-19 symptoms?
Disease control Recruiting nowThe main purpose of this study is to compare secutrelvir to placebo with respect to resolution of clinical symptoms in nonhospitalized participants with Coronavirus Disease 2019 (COVID-19) starting intervention within 48 hours of COVID-19 symptom onset.
Phase 3 • Sponsor: Shionogi • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a pill reverse eye bulging in thyroid eye disease?
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the efficacy, safety, and tolerability of linsitinib in participants with moderate to severe Thyroid Eye Disease (TED).
Phase 3 • Sponsor: Sling Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Stem cell transplant or drug combo: which better prevents leukemia return in seniors?
Disease control CancelledThe researchers are doing this study to find out if an allogeneic hematopoietic stem cell transplant (HSCT) or maintenance therapy with azacitidine and venetoclax is more effective at keeping AML from coming back (relapsing).
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can Stem-Cell implants restore movement in Parkinson's?
Disease control Not yet recruitingThis clinical study is designed to explore the safety and tolerability of UX-DA003. It will also explore if UX-DA003 works to improve motor function in subjects with Parkinson's disease.
Phase 1/2 • Sponsor: Shanghai UniXell Biotechnology Co., Ltd • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Double-Barreled drug attack targets Hard-to-Treat breast cancer
Disease control Not yet recruitingThe primary purpose of the study is to assess the safety, tolerability, and anti-tumor activity of HER3-DXd and T-DXd in the combination dosing regimens in participants with hormone receptor positive, HER2-low or HER2-ultralow, unresectable, or metastatic breast cancer.
Phase 1/2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Could fewer radiation sessions be just as effective for cervical cancer?
Disease control Recruiting nowThe goal of this clinical trial is to evaluate whether hypofractionated whole pelvic or extended-field concurrent chemoradiotherapy can improve treatment access and efficiency while potentially providing superior oncologic efficacy and safety compared to conventional chemoradioth…
Phase 3 • Sponsor: Mahidol University • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a Two-Drug attack stall resistant prostate cancer?
Disease control Recruiting nowHimalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or enzalutamide) or docetaxel for treating patients wit…
Phase 3 • Sponsor: ORIC Pharmaceuticals • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Magic mushroom compound could lift Veterans' depression
Symptom relief Recruiting nowThe purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (±) concurrent posttraumatic stress disorder.
Phase 3 • Sponsor: VA Office of Research and Development • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Can a new pill slow Parkinson's symptoms?
Disease control Not yet recruitingThis study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical trial designed to evaluate the efficacy, safety, and Pop PK characteristics of TJ0113 Capsules in treating EOPD patients. This study plans to enroll approximately 300 EOPD participants, w…
Phase 3 • Sponsor: Hangzhou PhecdaMed Co., Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can umbilical cord stem cells revive failing ovaries?
Disease control Recruiting nowA Phase I/IIa clinical study evaluating the safety, tolerability and efficacy of intravenously administered human umbilical cord mesenchymal stem cell (hUC-MSCs) injection in patients with premature ovarian insufficiency (POI). The primary objective of the Phase I dose-escalatio…
Phase 1/2 • Sponsor: Shenzhen Wingor Biotechnology Co., Ltd. • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC